Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR6 | P51684 | 15/20 | 0.45 |
| ▸ | CXCR2 | P25025 | 7/20 | 0.44 |
| ▸ | CXCR1 | P25024 | 3/20 | 0.44 |
| ▸ | CXCR3 | P49682 | 2/20 | 0.44 |
| ▸ | CCR4 | P51679 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15434981 | 1.00 | CCR6 (0.45) | CCR6CXCR2CXCR1CXCR3CCR4 | |
| SCHEMBL12424453 | 1.00 | CCR6 (0.45) | CCR6CXCR2CXCR1CXCR3CCR4 | |
| SCHEMBL1705871 | 0.90 | CXCR2 (0.52) | CCR6CXCR2CXCR1CXCR3CCR4 | |
| SCHEMBL12230777 | 0.89 | CCR6 (0.46) | CCR6CXCR2CXCR1CXCR3CCR4 | |
| SCHEMBL1706345 | 0.88 | CCR6 (0.48) | CCR6CXCR2CXCR1CXCR3CCR4 | |
| SCHEMBL2295589 | 0.88 | CCR6 (0.44) | CCR6CXCR2CXCR1CXCR3CCR4 | |
| SCHEMBL2298903 | 0.88 | CCR6 (0.44) | CCR6CXCR2CXCR1CXCR3CCR4 | |
| SCHEMBL12385987 | 0.88 | CCR6 (0.44) | CCR6CXCR2CXCR1CXCR3CCR4 | |
| SCHEMBL2295596 | 0.88 | CCR6 (0.44) | CCR6CXCR2CXCR1CXCR3CCR4 | |
| SCHEMBL13494769 | 0.88 | CCR6 (0.44) | CCR6CXCR2CXCR1CXCR3CCR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9115087-B2 | Squaramide derivatives as CXCR2 antagonist | NOVARTIS AG (CH) | 2015-08-25 | — | — | US | disclosed |
| US-9115087-B2 | Squaramide derivatives as CXCR2 antagonist | NOVARTIS AG (CH) | 2015-08-25 | — | — | US | disclosed |
| US-9115087-B2 | Squaramide derivatives as CXCR2 antagonist | NOVARTIS AG (CH) | 2015-08-25 | — | — | US | disclosed |
| US-20140213594-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2014-07-31 | — | — | US | disclosed |
| US-20140213594-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2014-07-31 | — | — | US | disclosed |
| US-20140213594-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2014-07-31 | — | — | US | disclosed |
| US-8722925-B2 | Squaramide derivatives as CXCR2 antagonist | NOVARTIS AG (CH) | 2014-05-13 | — | — | US | disclosed |
| US-8722925-B2 | Squaramide derivatives as CXCR2 antagonist | NOVARTIS AG (CH) | 2014-05-13 | — | — | US | disclosed |
| US-8722925-B2 | Squaramide derivatives as CXCR2 antagonist | NOVARTIS AG (CH) | 2014-05-13 | — | — | US | disclosed |
| EP-2310359-B1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2014-01-15 | — | — | EP | disclosed |
| US-20110251205-A1 | SQUARAMIDE DERIVATIVES AS CXCR2 ANTAGONIST | NOVARTIS AG | 2011-10-13 | — | — | US | disclosed |
| US-20110251205-A1 | SQUARAMIDE DERIVATIVES AS CXCR2 ANTAGONIST | NOVARTIS AG | 2011-10-13 | — | — | US | disclosed |
| US-20110251205-A1 | SQUARAMIDE DERIVATIVES AS CXCR2 ANTAGONIST | NOVARTIS AG | 2011-10-13 | — | — | US | disclosed |
| US-20110251206-A1 | Squaramide derivatives as CXCR2 antagonist | NOVARTIS AG | 2011-10-13 | — | — | US | disclosed |
| US-7989497-B2 | Squaramide derivatives as CXCR2 antagonist | NOVARTIS AG (CH) | 2011-08-02 | — | — | US | disclosed |
| US-7989497-B2 | Squaramide derivatives as CXCR2 antagonist | NOVARTIS AG (CH) | 2011-08-02 | — | — | US | disclosed |
| US-7989497-B2 | Squaramide derivatives as CXCR2 antagonist | NOVARTIS AG (CH) | 2011-08-02 | — | — | US | disclosed |
| WO-2010015613-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2010-02-11 | — | — | WO | disclosed |
| US-20100029670-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2010-02-04 | — | — | US | disclosed |
| US-20100029670-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2010-02-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110251206-A1 | Squaramide derivatives as CXCR2 antagonist | CXCR2, CXCR3, CXCR1 | CCR6 57/4885CXCR2 1/4885CXCR1 3/4885 |
| US-20110251205-A1 | SQUARAMIDE DERIVATIVES AS CXCR2 ANTAGONIST | CXCR2, CXCR3, CXCR1 | CCR6 57/4885CXCR2 1/4885CXCR1 3/4885 |
| US-20100029670-A1 | ORGANIC COMPOUNDS | CXCR2, CXCR1, CXCR3 | CCR6 30/4885CXCR2 1/4885CXCR1 2/4885 |
| US-20140213594-A1 | ORGANIC COMPOUNDS | CXCR2, CXCR1, CXCR3 | CCR6 30/4885CXCR2 1/4885CXCR1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.